Clinical Report: Phase 3 Win for TED Therapy
Overview
Amgen's phase 3 trial of subcutaneous teprotumumab (TEPEZZA) in patients with moderate-to-severe active thyroid eye disease (TED) demonstrated significant efficacy, with 77% of patients achieving a proptosis response at 24 weeks. The study met both primary and key secondary endpoints, indicating a promising alternative to intravenous administration.
Background
Thyroid eye disease (TED) is a progressive autoimmune condition that can severely impact vision and quality of life. Current treatment options include intravenous teprotumumab, the only approved therapy for TED, which has shown significant efficacy. The development of a subcutaneous formulation aims to enhance patient convenience and accessibility while maintaining therapeutic effectiveness.
Data Highlights
| Endpoint | Subcutaneous TEPEZZA | Placebo |
|---|---|---|
| Proptosis Response at 24 Weeks | 77% | 19.6% |
| Mean Proptosis Reduction | -3.17 mm | N/A |
Key Findings
- 77% of patients receiving subcutaneous TEPEZZA achieved a proptosis response at 24 weeks.
- Mean proptosis reduction reached -3.17 mm, consistent with previous IV formulation outcomes.
- Statistically significant improvements were observed in overall responder rates, Clinical Activity Score (CAS), diplopia outcomes, and quality of life measures.
- Safety profile was consistent with IV TEPEZZA, with common adverse events including muscle spasms and gastrointestinal symptoms.
- Mild-to-moderate injection site reactions were reported but did not lead to treatment discontinuation.
Clinical Implications
The introduction of subcutaneous TEPEZZA may provide a more convenient treatment option for patients with TED, potentially improving adherence and access to therapy. Clinicians should consider this formulation as a viable alternative to intravenous administration, particularly for patients seeking less burdensome treatment options.
Conclusion
The positive results from the phase 3 trial of subcutaneous TEPEZZA suggest a significant advancement in the management of TED, offering comparable efficacy to the intravenous formulation while enhancing patient convenience.
References
- Amgen Inc., PR Newswire, 2023 -- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
- Ophthalmology Management — Viridian Reports Positive Results From Phase 3 Trial in Chronic TED
- Ophthalmology Management — Viridian Theraputics Announces Topline Results for Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
- dana-farber — ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
- The Journal of Clinical Endocrinology & Metabolism — Evaluation of Auditory Impairment in Individuals With Graves’ Disease and Thyroid Eye Disease With or Without Teprotumumab Treatment
- Viridian Reports Positive Results From Phase 3 Trial in Chronic TED
- Viridian Theraputics Announces Topline Results for Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
- https://academic.oup.com/ejendo/article/185/4/G43/6654384
- Teprotumumab for the Treatment of Active Thyroid Eye Disease - PubMed
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE | Amgen Inc.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
